AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach(Mayo Clinic in Arizona), Laura Kulik(Northwestern University), Richard S. Finn(University of California, Los Angeles), Claude B. Sirlin(University of California, San Diego), Michaël Abécassis(Northwestern University), Lewis R. Roberts(Mayo Clinic in Arizona), Andrew X. Zhu(Massachusetts General Hospital), M. Hassan Murad(WinnMed), Jorge A. Marrero(The University of Texas Southwestern Medical Center)
Hepatology
January 28, 2017
Cited by 4,148Open Access
Full Text

Abstract

This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the surveillance, diagnosis, and treatment of hepatocellular carcinoma (HCC) occurring in the setting of adults with cirrhosis. Unlike previous AASLD practice guidelines, the current guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of the guideline can be obtained by reading the applicable portions of the systematic reviews. In addition, more detailed information may be found in the associated guidance document related to clinically important aspects of HCC that lacked sufficient evidence to warrant a systematic review.


Related Papers